Zoetis Inc. (NYSE:ZTS) Shares Bought by Appleton Partners Inc. MA

Appleton Partners Inc. MA grew its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 1.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 88,617 shares of the company’s stock after buying an additional 1,428 shares during the quarter. Zoetis accounts for 1.2% of Appleton Partners Inc. MA’s investment portfolio, making the stock its 21st largest position. Appleton Partners Inc. MA’s holdings in Zoetis were worth $14,995,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Zoetis by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 40,334,966 shares of the company’s stock worth $7,960,912,000 after purchasing an additional 536,477 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after purchasing an additional 3,244,074 shares during the period. Wellington Management Group LLP raised its stake in shares of Zoetis by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after acquiring an additional 297,044 shares during the period. Capital World Investors lifted its holdings in shares of Zoetis by 0.6% in the 4th quarter. Capital World Investors now owns 9,064,158 shares of the company’s stock worth $1,788,988,000 after acquiring an additional 57,798 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Zoetis by 3.3% in the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after purchasing an additional 196,771 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS traded down $0.74 on Tuesday, reaching $170.16. The stock had a trading volume of 647,593 shares, compared to its average volume of 2,938,766. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The stock has a market cap of $77.64 billion, a P/E ratio of 32.84, a price-to-earnings-growth ratio of 2.65 and a beta of 0.89. The business’s 50-day moving average price is $165.85 and its 200 day moving average price is $179.50. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.31 earnings per share. As a group, equities analysts expect that Zoetis Inc. will post 5.76 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 annualized dividend and a yield of 1.02%. Zoetis’s dividend payout ratio is currently 33.33%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several research reports. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group cut their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Barclays lowered their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. HSBC reduced their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $211.75.

View Our Latest Report on Zoetis

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at approximately $2,237,316. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.